20/20 Biolabs, Inc.

20/20 Biolabs, Inc. is a commercial-stage diagnostics company dedicated to developing and commercializing AI-powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company's core mission is to leverage machine learning and real-world data to enhance diagnostic accuracy and clinical utility. Headquartered in Gaithersburg, Maryland, 20/20 Biolabs operates a CAP-accredited and CLIA-licensed laboratory.

The company offers two primary product lines under its OneTest brand: OneTest for Cancer and OneTest for Longevity. OneTest for Cancer is a multi-cancer early detection (MCED) blood test that utilizes a protein tumor marker approach to detect various cancers, including lung, pancreatic, ovarian, and liver, at earlier stages. It is designed for convenient at-home collection. OneTest for Longevity, anticipated to launch in the first half of 2026, measures inflammatory biomarkers associated with chronic conditions such as heart disease, cancers, dementia, diabetes, and mental health.

20/20 Biolabs began trading on the Nasdaq Capital Market under the ticker symbol AIDX on February 19, 2026. Recent developments include a partnership with Evexia Diagnostics in April 2026 to make OneTest for Cancer available to Evexia's network of over 40,000 practitioners, and an exclusive U.S. license agreement with ROKIT Healthcare in March 2026 to integrate advanced chronic kidney disease prediction technology into its Longevity Test Program. The company reported a 17% increase in full-year 2025 revenue to $2.0 million and secured a contingent financing agreement for up to $40 million. Jonathan Cohen serves as the President and CEO.